

Mdm-2: "big brother" of p53

Journal of Cellular Biochemistry
64, 343-52

Citation Report

#	ARTICLE	IF	CITATIONS
1	Increased Mdm2 Expression in Rat Brain after Transient Middle Cerebral Artery Occlusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 658-669.	4.3	32
2	MDM-2 Oncoprotein Overexpression, p53 Gene Mutation, and VEGF Up-Regulation in Angiosarcomas. <i>American Journal of Pathology</i> , 1998, 153, 1425-1433.	3.8	158
3	The MDM2 gene amplification database. <i>Nucleic Acids Research</i> , 1998, 26, 3453-3459.	14.5	843
4	The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb. <i>Molecular and Cellular Biology</i> , 1998, 18, 3974-3982.	2.3	129
5	MDM2 Suppresses p73 Function without Promoting p73 Degradation. <i>Molecular and Cellular Biology</i> , 1999, 19, 3257-3266.	2.3	302
6	MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. <i>Oncogene</i> , 1999, 18, 1419-1434.	5.9	36
7	Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. <i>Oncogene</i> , 1999, 18, 1935-1944.	5.9	261
8	p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. <i>Oncogene</i> , 1999, 18, 1921-1934.	5.9	118
9	Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. <i>Oncogene</i> , 1999, 18, 3205-3212.	5.9	189
10	ATM: A mediator of multiple responses to genotoxic stress. <i>Oncogene</i> , 1999, 18, 6135-6144.	5.9	256
11	A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein. <i>Oncogene</i> , 1999, 18, 7026-7033.	5.9	9
12	p53 and Ki-67 Proliferating Cell Nuclear Antigen in Benign and Malignant Peripheral Nerve Sheath Tumors in Children. <i>Pediatric and Developmental Pathology</i> , 1999, 2, 377-384.	1.0	41
13	Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. <i>EMBO Journal</i> , 1999, 18, 1805-1814.	7.8	321
14	Insulin-Like Growth Factor-1 Induces Mdm2 and Down-Regulates p53, Attenuating the Myocyte Renin-Angiotensin System and Stretch-Mediated Apoptosis. <i>American Journal of Pathology</i> , 1999, 154, 567-580.	3.8	107
15	Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. <i>Oncogene</i> , 2000, 19, 1635-1646.	5.9	134
16	Defect in the p53-Mdm2 Autoregulatory Loop Resulting from Inactivation of TAF II 250 in Cell Cycle Mutant tsBN462 Cells. <i>Molecular and Cellular Biology</i> , 2000, 20, 5554-5570.	2.3	9
17	The p53 Tumor Suppressor Protein Does Not Regulate Expression of Its Own Inhibitor, MDM2, Except under Conditions of Stress. <i>Molecular and Cellular Biology</i> , 2000, 20, 2023-2030.	2.3	80
18	High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 2646-2651.	7.1	124

#	ARTICLE	IF	CITATIONS
19	bcl-2 overexpression promotes myocyte proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6257-6262.	7.1	94
20	ARF Function Does Not Require p53 Stabilization or Mdm2 Relocalization. Molecular and Cellular Biology, 2002, 22, 196-206.	2.3	116
21	The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation. Oncogene, 2002, 21, 2376-2386.	5.9	10
22	Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells. Oncogene, 2002, 21, 2605-2610.	5.9	15
23	Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene, 2002, 21, 3525-3531.	5.9	10
24	Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO Journal, 2003, 22, 1442-1450.	7.8	112
25	Myc pathways provoking cell suicide and cancer. Oncogene, 2003, 22, 9007-9021.	5.9	420
26	Bax translocation and mitochondrial fragmentation induced by Helicobacter pylori. Gut, 2004, 53, 805-813.	12.1	52
27	Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene, 2004, 23, 4050-4059.	5.9	66
28	Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. Journal of Cancer Research and Clinical Oncology, 2005, 131, 617-623.	2.5	14
29	The role of NBS1 in the modulation of PIKK family proteins ATM and ATR in the cellular response to DNA damage. Cancer Letters, 2006, 243, 9-15.	7.2	35
30	Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene, 2006, 25, 6672-6677.	5.9	22
31	H.Âpylori-induced Apoptosis in Human Gastric Cancer Cells Mediated via the Release of Apoptosis-inducing Factor from Mitochondria. Helicobacter, 2008, 13, 506-517.	3.5	38
32	Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer, 2008, 8, 113.	2.6	16
33	p53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1786, 15-23.	7.4	56
34	Human Papillomavirus Seropositivity Synergizes with MDM2 Variants to Increase the Risk of Oral Squamous Cell Carcinoma. Cancer Research, 2010, 70, 7199-7208.	0.9	42
35	Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma. Oncology Letters, 2011, 2, 707-712.	1.8	4
36	Murine Double Minute Clone 2 309T/G and 285G/C Promoter Single Nucleotide Polymorphism as a Risk Factor for Breast Cancer: A Polish Experience. International Journal of Biological Markers, 2012, 27, 105-110.	1.8	10

#	ARTICLE	IF	CITATIONS
37	EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1886-1899.	7.3	74
38	RNA interference against MDM2 suppresses tumor growth and metastasis in pancreatic carcinoma SW1990HM cells. <i>Molecular and Cellular Biochemistry</i> , 2014, 387, 1-8.	3.1	13
39	Pro-angiogenic effects of MDM2 through HIF-1 α and NF- κ B mediated mechanisms in LNCaP prostate cancer cells. <i>Molecular Biology Reports</i> , 2014, 41, 5533-5541.	2.3	8
40	2,3-Bis(1H-indole) heterocycles: New p53/MDM2/MDMX antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5661-5666.	2.2	32
41	How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures. <i>ChemMedChem</i> , 2016, 11, 757-772.	3.2	84
42	Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. <i>Oncology Letters</i> , 2017, 13, 2483-2489.	1.8	25
43	Investigation of the association between the MDM2 T309G polymorphism and gastric cancer. <i>Biomedical Reports</i> , 2017, 7, 469-473.	2.0	7
44	Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b] indole Derivatives as Broad-Spectrum Potent Anticancer Agents. <i>Drug Designing: Open Access</i> , 2017, 06, .	0.2	11
45	Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3741-3752.	4.3	25
46	Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice. <i>Cell Communication and Signaling</i> , 2018, 16, 93.	6.5	17
47	Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC. <i>Cancers</i> , 2021, 13, 199.	3.7	8
48	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). <i>Oncotarget</i> , 2014, 5, 8223-8234.	1.8	22
49	MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk. <i>Oncotarget</i> , 2011, 2, 251-258.	1.8	39
50	Expression of mutant type-p53 products in H pylori-associated chronic gastritis. <i>World Journal of Gastroenterology</i> , 2007, 13, 1541.	3.3	32
51	The 40bp indel polymorphism of increase the risk of cancer: An updated meta-analysis. <i>Molecular Biology Research Communications</i> , 2019, 8, 1-8.	0.3	11
52	Mdm2: the ups and downs. <i>Molecular Medicine</i> , 1999, 5, 71-83.	4.4	58
53	Regulation of p53 Function by Formation of Non-Nuclear Heterologous Protein Complexes. <i>Biomolecules</i> , 2022, 12, 327.	4.0	5